An Open-label, Phase I/II Trial to Determine the Maximum Tolerated Dose and Investigate Safety, Pharmacokinetics and Efficacy of BI 836858 in Combination With Decitabine in Patients With Acute Myeloid Leukemia
Phase of Trial: Phase I/II
Latest Information Update: 11 Jan 2018
At a glance
- Drugs BI 836858 (Primary) ; Decitabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 27 Nov 2017 Planned End Date changed from 12 Oct 2019 to 12 Jan 2020.
- 27 Nov 2017 Planned primary completion date changed from 12 Oct 2019 to 12 Jan 2020.
- 15 May 2017 Planned End Date changed from 13 Apr 2019 to 12 Oct 2019.